Jed E Rose1, James M Davis2,3. 1. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC. 2. Division of Internal Medicine, Department of Medicine, Duke University, Durham, NC. 3. Duke Cancer Institute, Durham, NC.
Abstract
INTRODUCTION: This study explored the efficacy of combination lorcaserin and nicotine patch for smoking cessation treatment and prevention of postsmoking cessation weight gain. METHODS: We conducted a trial in which 61 adult daily smokers were asked to quit smoking using a combination of lorcaserin and nicotine patch. During the first 2 weeks of treatment prior to the quit day, participants were randomized to receive either lorcaserin (10 mg twice daily) plus nicotine patch (21 mg) or placebo plus nicotine patch (21 mg). Following this 2-week period, participants received both medications for 12 weeks. Outcomes included 4-week continuous smoking abstinence at the end of treatment (weeks 7-10 postquit attempt), weight change, ad libitum smoking, withdrawal symptoms, and ratings of cigarette reward. RESULTS: Biochemically confirmed continuous smoking abstinence from 7 to 10 weeks postquit attempt was 31.1% (90% confidence interval, 21.4%-40.8%). Participants who quit smoking showed no weight gain; in fact, mean weight change was minus 0.16 kg (SD = 3.27) over the study period. There was an unexpected but strong association (p = .006) between a decrease in sensory enjoyment of smoking and successful quit outcome on this regimen. During the prequit randomization period, lorcaserin versus placebo reduced the impact of smoking to relieve craving for cigarettes as well as the sensory enjoyment of smoking (p = .005). Adherence and tolerability to lorcaserin and nicotine patch was good. CONCLUSIONS: The combination of lorcaserin and nicotine patch was well tolerated, associated with a relatively high smoking abstinence rate, and effectively prevented weight gain associated with quitting smoking. IMPLICATIONS: This report provides an important contribution to the literature because it details evidence of a medication combination-lorcaserin and nicotine-that is effective for smoking cessation and for ameliorating weight gain associated with smoking cessation. For many smokers, postcessation weight gain is a major obstacle to quitting, and this medication combination provides a suitable treatment option for these smokers. CLINICAL TRIAL REGISTRATION: NCT02906644.
RCT Entities:
INTRODUCTION: This study explored the efficacy of combination lorcaserin and nicotine patch for smoking cessation treatment and prevention of postsmoking cessation weight gain. METHODS: We conducted a trial in which 61 adult daily smokers were asked to quit smoking using a combination of lorcaserin and nicotine patch. During the first 2 weeks of treatment prior to the quit day, participants were randomized to receive either lorcaserin (10 mg twice daily) plus nicotine patch (21 mg) or placebo plus nicotine patch (21 mg). Following this 2-week period, participants received both medications for 12 weeks. Outcomes included 4-week continuous smoking abstinence at the end of treatment (weeks 7-10 postquit attempt), weight change, ad libitum smoking, withdrawal symptoms, and ratings of cigarette reward. RESULTS: Biochemically confirmed continuous smoking abstinence from 7 to 10 weeks postquit attempt was 31.1% (90% confidence interval, 21.4%-40.8%). Participants who quit smoking showed no weight gain; in fact, mean weight change was minus 0.16 kg (SD = 3.27) over the study period. There was an unexpected but strong association (p = .006) between a decrease in sensory enjoyment of smoking and successful quit outcome on this regimen. During the prequit randomization period, lorcaserin versus placebo reduced the impact of smoking to relieve craving for cigarettes as well as the sensory enjoyment of smoking (p = .005). Adherence and tolerability to lorcaserin and nicotine patch was good. CONCLUSIONS: The combination of lorcaserin and nicotine patch was well tolerated, associated with a relatively high smoking abstinence rate, and effectively prevented weight gain associated with quitting smoking. IMPLICATIONS: This report provides an important contribution to the literature because it details evidence of a medication combination-lorcaserin and nicotine-that is effective for smoking cessation and for ameliorating weight gain associated with smoking cessation. For many smokers, postcessation weight gain is a major obstacle to quitting, and this medication combination provides a suitable treatment option for these smokers. CLINICAL TRIAL REGISTRATION: NCT02906644.
Authors: Sherry A McKee; Andrea H Weinberger; Julia Shi; Jeanette Tetrault; Sabrina Coppola Journal: Nicotine Tob Res Date: 2012-04-06 Impact factor: 4.244
Authors: Joseph C Cappelleri; Andrew G Bushmakin; Christine L Baker; Elizabeth Merikle; Abayomi O Olufade; David G Gilbert Journal: Addict Behav Date: 2006-07-27 Impact factor: 3.913
Authors: Vincenzo Teneggi; Stephen T Tiffany; Lisa Squassante; Stefano Milleri; Luigi Ziviani; Alan Bye Journal: Psychopharmacology (Berl) Date: 2002-08-27 Impact factor: 4.530
Authors: Daniel J O Roche; Spencer Bujarski; Nathasha R Moallem; Iris Guzman; Jenessa R Shapiro; Lara A Ray Journal: Psychopharmacology (Berl) Date: 2014-02-06 Impact factor: 4.530
Authors: William R Shanahan; Jed E Rose; Alan Glicklich; Scott Stubbe; Matilde Sanchez-Kam Journal: Nicotine Tob Res Date: 2017-08-01 Impact factor: 4.244
Authors: Cristiano Bombardi; Francis Delicata; Claudio Tagliavia; Annamaria Grandis; Massimo Pierucci; Antonella Marino Gammazza; Maurizio Casarrubea; Philippe De Deurwaerdère; Giuseppe Di Giovanni Journal: Int J Mol Sci Date: 2021-04-30 Impact factor: 5.923
Authors: Ryan T Hurt; Ivana T Croghan; Darrell R Schroeder; Doo-Sup Choi; Karen Fischer; Shawn Fokken; Jon O Ebbert Journal: Mayo Clin Proc Innov Qual Outcomes Date: 2022-09-21